I 
114TH CONGRESS 
1ST SESSION H. R. 2805 
To address prescription opioid abuse and heroin use. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 17, 2015 
Mrs. BROOKS of Indiana (for herself, Mr. KENNEDY, Mr. CARSON of Indiana, 
Mrs. WALORSKI, Mr. WHITFIELD, and Mr. MESSER) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce, and in addition to the Committee on the Judiciary, for a period 
to be subsequently determined by the Speaker, in each case for consider-
ation of such provisions as fall within the jurisdiction of the committee 
concerned 
A BILL 
To address prescription opioid abuse and heroin use. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Heroin and Prescrip-
tion Opioid Abuse Prevention, Education, and Enforce-
ment Act of 2015’’. 
SEC. 2. FINDINGS. 
Congress makes the following findings: 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(1) The Controlled Substances Act (21 U.S.C. 
801 et seq.) declares that many controlled sub-
stances have a useful and legitimate medical purpose 
and are necessary to maintain the health and gen-
eral welfare of the people of the United States. 
(2) Health care professionals, medical experts, 
researchers, and scientists have found pain to be a 
major national health problem. 
(3) The responsible treatment of pain is a high 
priority for our Nation and the needs of individuals 
with pain must be taken into careful consideration 
when taking steps to prevent prescription drug mis-
use and abuse. 
(4) When no longer needed or wanted for legiti-
mate pain management or health treatment, pre-
scription opioids are susceptible to diversion. Pre-
scription opioids also may be abused by individuals 
who were not prescribed such drugs, or misused by 
individuals not taking such drugs as directed. 
(5) Approximately 4 out of 5 new heroin users 
report that they became addicted to prescription 
opioids before they used heroin for the first time. 
(6) According to the National Institute on Drug 
Abuse, heroin attaches to the same brain cell recep-
tors as prescription opioids. 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(7) The low cost and high purity of currently 
available heroin has contributed to an increase in 
heroin use across the United States. 
(8) More people are using heroin, and are using 
heroin at a younger age. The National Survey on 
Drug Use and Health reports that new heroin users 
numbered 142,000 in 2010, and increased to 
178,000 in 2011. In 2011, the average age at first 
use among heroin abusers between 12 and 49 years 
was 22.1 years. In 2009, the average age at first use 
among heroin abusers between 12 and 49 years was 
25.5 years. 
(9) According to the Department of Health and 
Human Services, heroin use nationwide rose 79 per-
cent between 2007 and 2012. 
(10) Deaths from heroin overdose have signifi-
cantly increased in communities across the United 
States. According to the Centers for Disease Control 
and Prevention, the number of deaths involving her-
oin almost tripled between 2010 and 2013. From 
2010 to 2013, the number of heroin deaths rose 
from 3,036 to 8,257. 
(11) The Edward Byrne Memorial Justice As-
sistance Grant Program under part E of title I of 
the Omnibus Crime Control and Safe Streets Act of 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
1968 (42 U.S.C. 3750 et seq.) is critical to fighting 
the prescription opioid abuse and heroin use 
epidemics, and should be reauthorized and fully 
funded. 
SEC. 3. DEVELOPMENT OF BEST PRESCRIBING PRACTICES. 
(a) INTER-AGENCY TASK FORCE.—Not later than 
120 days after the date of enactment of this Act, the Sec-
retary of Health and Human Services (referred to in this 
section as the ‘‘Secretary’’), in cooperation with the Sec-
retary of Veterans Affairs, the Secretary of Defense, and 
the Administrator of the Drug Enforcement Administra-
tion, shall convene a Pain Management Best Practices 
Inter-Agency Task Force (referred to in this section as 
the ‘‘task force’’). 
(b) MEMBERSHIP.—The task force shall be com-
prised of— 
(1) representatives of— 
(A) the Department of Health and Human 
Services, including the Centers for Disease Con-
trol and Prevention; 
(B) the Department of Veterans Affairs; 
(C) the Department of Defense; 
(D) the Drug Enforcement Administration; 
(E) the Office of National Drug Control 
Policy; and 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(F) the Institute of Medicine; and 
(2) the Director of the National Institutes of 
Health; 
(3) physicians, dentists, and non-physician pre-
scribers; 
(4) pharmacists; 
(5) experts in the fields of pain research and 
addiction research; 
(6) representatives of— 
(A) pain management professional organi-
zations; 
(B) the mental health treatment commu-
nity; 
(C) the addiction treatment community; 
and 
(D) pain advocacy groups; 
(7) a person in recovery from addiction to medi-
cation for chronic pain; 
(8) a person with chronic pain; and 
(9) other stakeholders, as the Secretary deter-
mines appropriate. 
(c) DUTIES.—The task force shall— 
(1) not later than 180 days after the date on 
which the task force is convened, develop best prac-
tices for pain management and prescription pain 
VerDate Sep 11 2014 
00:36 Jun 23, 2015
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
medication prescribing practices, taking into consid-
eration— 
(A) existing pain management research; 
(B) recommendations from relevant con-
ferences; and 
(C) ongoing efforts at the State and local 
levels and by medical professional organizations 
to develop improved pain management strate-
gies; 
(2) solicit and take into consideration public 
comment on the best practices developed under para-
graph (1), amending such best practices if appro-
priate; and 
(3) develop a strategy for disseminating infor-
mation about the best practices developed under 
paragraphs (1) and (2) to prescribers, pharmacists, 
State medical boards, educational institutions that 
educate prescribers and pharmacists, and other par-
ties, as the Secretary determines appropriate. 
(d) LIMITATION.—The task force shall not have rule-
making authority. 
(e) REPORT.—Not later than 270 days after the date 
on which the task force is convened under subsection (a), 
the task force shall submit to Congress a report that in-
cludes— 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(1) the strategy for disseminating best practices 
developed under subsection (c); 
(2) the results of a feasibility study on linking 
best practices developed under paragraphs (1) and 
(2) of subsection (c) to receiving and renewing reg-
istrations under section 303(f) of the Controlled 
Substances Act (21 U.S.C. 823(f)); and 
(3) recommendations on how to apply such best 
practices to improve prescribing practices at medical 
facilities, including medical facilities of the Veterans 
Health Administration. 
SEC. 4. AMENDMENTS TO CONTROLLED SUBSTANCE MONI-
TORING PROGRAM. 
Section 399O of the Public Health Service Act (42 
U.S.C. 280g–3) is amended— 
(1) in subsection (a)— 
(A) in paragraph (1)— 
(i) in subparagraph (A), by striking 
‘‘or’’; 
(ii) in subparagraph (B), by striking 
the period at the end and inserting ‘‘; or’’; 
and 
(iii) by adding at the end the fol-
lowing: 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
‘‘(C) to maintain and operate an existing 
State-controlled 
substance 
monitoring 
pro-
gram.’’; and 
(B) in paragraph (3), by inserting ‘‘by the 
Secretary’’ after ‘‘Grants awarded’’; 
(2) by amending subsection (b) to read as fol-
lows: 
‘‘(b) MINIMUM
REQUIREMENTS.—The Secretary 
shall maintain and, as appropriate, supplement or revise 
(after publishing proposed additions and revisions in the 
Federal Register and receiving public comments thereon) 
minimum requirements for criteria to be used by States 
for purposes of clauses (ii), (v), (vi), and (vii) of subsection 
(c)(1)(A).’’; 
(3) in subsection (c)— 
(A) in paragraph (1)(B)— 
(i) in the matter preceding clause (i), 
by striking ‘‘(a)(1)(B)’’ and inserting 
‘‘(a)(1)(B) or (a)(1)(C)’’; 
(ii) in clause (i), by striking ‘‘program 
to be improved’’ and inserting ‘‘program to 
be improved or maintained’’; 
(iii) by redesignating clauses (iii) and 
(iv) as clauses (iv) and (v), respectively; 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(iv) by inserting after clause (ii) the 
following: 
‘‘(iii) a plan to apply the latest ad-
vances in health information technology in 
order to incorporate prescription drug 
monitoring program data directly into the 
workflow of prescribers and dispensers to 
ensure timely access to patients’ controlled 
prescription drug history;’’; 
(v) in clause (iv), as redesignated, by 
inserting before the semicolon at the end 
‘‘and at least one health information tech-
nology system such as an electronic health 
records system, a health information ex-
change, or an e-prescribing system’’; and 
(vi) in clause (v), as redesignated, by 
striking ‘‘public health’’ and inserting 
‘‘public health or public safety’’; 
(B) in paragraph (3)— 
(i) by striking ‘‘If a State that sub-
mits’’ and inserting the following: 
‘‘(A) IN GENERAL.—If a State that sub-
mits’’; 
(ii) by striking the period at the end 
and inserting ‘‘and include timelines for 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
full implementation of such interoper-
ability. The State shall also describe the 
manner in which it will achieve interoper-
ability between its monitoring program and 
health information technology systems, as 
allowable under State law, and include 
timelines for implementation of such inter-
operability.’’; and 
(iii) by adding at the end the fol-
lowing: 
‘‘(B) MONITORING
OF
EFFORTS.—The 
Secretary shall monitor State efforts to achieve 
interoperability, as described in subparagraph 
(A).’’; 
(C) in paragraph (5)— 
(i) by striking ‘‘implement or im-
prove’’ and inserting ‘‘establish, improve, 
or maintain’’; and 
(ii) by adding at the end the fol-
lowing: ‘‘The Secretary shall redistribute 
any funds that are so returned among the 
remaining grantees under this section in 
accordance with the formula described in 
subsection (a)(2)(B).’’; 
(4) in subsection (d)— 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(A) in the matter preceding paragraph 
(1)— 
(i) by striking ‘‘In implementing or 
improving’’ and all that follows through 
‘‘(a)(1)(B)’’ and inserting ‘‘In establishing, 
improving, or maintaining a controlled sub-
stance monitoring program under this sec-
tion, a State shall comply, or with respect 
to a State that applies for a grant under 
subparagraph (B) or (C) of subsection 
(a)(1)’’; and 
(ii) by striking ‘‘public health’’ and in-
serting ‘‘public health or public safety’’; 
and 
(B) by adding at the end the following: 
‘‘(5) The State shall report to the Secretary 
on— 
‘‘(A) as appropriate, interoperability with 
the controlled substance monitoring programs 
of Federal departments and agencies; 
‘‘(B) as appropriate, interoperability with 
health information technology systems such as 
electronic health records systems, health infor-
mation exchanges, and e-prescribing systems; 
and 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
‘‘(C) whether or not the State provides 
automatic, real-time or daily information about 
a patient when a practitioner (or the designee 
of a practitioner, where permitted) requests in-
formation about such patient.’’; 
(5) in subsections (e), (f)(1), and (g), by strik-
ing ‘‘implementing or improving’’ each place it ap-
pears and inserting ‘‘establishing, improving, or 
maintaining’’; 
(6) in subsection (f)— 
(A) in paragraph (1)— 
(i) in subparagraph (B), by striking 
‘‘misuse of a schedule II, III, or IV sub-
stance’’ and inserting ‘‘misuse of a con-
trolled substance included in schedule II, 
III, or IV of section 202(c) of the Con-
trolled Substance Act’’; and 
(ii) in subparagraph (D), by inserting 
‘‘a State substance abuse agency,’’ after ‘‘a 
State health department,’’; and 
(B) by adding at the end the following: 
‘‘(3) EVALUATION
AND
REPORTING.—Subject 
to subsection (g), a State receiving a grant under 
subsection (a) shall provide the Secretary with ag-
gregate data and other information determined by 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
the Secretary to be necessary to enable the Sec-
retary— 
‘‘(A) to evaluate the success of the State’s 
program in achieving its purposes; or 
‘‘(B) to prepare and submit the report to 
Congress required by subsection (l)(2). 
‘‘(4) RESEARCH BY OTHER ENTITIES.—A de-
partment, program, or administration receiving non-
identifiable information under paragraph (1)(D) 
may make such information available to other enti-
ties for research purposes.’’; 
(7) by redesignating subsections (h) through 
(n) as subsections (j) through (p), respectively; 
(8) in subsections (c)(1)(A)(iv) and (d)(4), by 
striking ‘‘subsection (h)’’ each place it appears and 
inserting ‘‘subsection (j)’’; 
(9) by inserting after subsection (g) the fol-
lowing: 
‘‘(h) EDUCATION AND ACCESS TO THE MONITORING 
SYSTEM.—A State receiving a grant under subsection (a) 
shall take steps to— 
‘‘(1) facilitate prescriber and dispenser use of 
the State’s controlled substance monitoring system; 
‘‘(2) educate prescribers and dispensers on the 
benefits of the system both to them and society; and 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
‘‘(3) facilitate linkage to the State substance 
abuse agency and substance abuse disorder services. 
‘‘(i) CONSULTATION WITH ATTORNEY GENERAL.— 
In carrying out this section, the Secretary shall consult 
with the Attorney General of the United States and other 
relevant Federal officials to— 
‘‘(1) ensure maximum coordination of controlled 
substance monitoring programs and related activi-
ties; and 
‘‘(2) minimize duplicative efforts and funding.’’; 
(10) in subsection (l)(2)(A), as redesignated by 
paragraph (7)— 
(A) in clause (ii), by inserting ‘‘; estab-
lished or strengthened initiatives to ensure link-
ages to substance use disorder services;’’ before 
‘‘or affected patient access’’; and 
(B) in clause (iii), by inserting ‘‘and be-
tween controlled substance monitoring pro-
grams and health information technology sys-
tems,’’ before ‘‘, including an assessment’’; 
(11) by striking subsection (m) (relating to 
preference), as redesignated by paragraph (7); 
(12) by redesignating subsections (m) through 
(o), as redesignated by paragraph (7), as subsections 
(l) through (o), respectively; 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(13) in subsection (m)(1), as redesignated by 
paragraph (12), by striking ‘‘establishment, imple-
mentation, or improvement’’ and inserting ‘‘estab-
lishment, improvement, or maintenance’’; 
(14) in subsection (n)— 
(A) in paragraph (5)— 
(i) by striking ‘‘means the ability’’ 
and inserting the following: ‘‘means— 
‘‘(A) the ability’’; 
(ii) by striking the period at the end 
and inserting ‘‘; or’’; and 
(iii) by adding at the end the fol-
lowing: 
‘‘(B) sharing of State controlled substance 
monitoring program information with a health 
information technology system such as an elec-
tronic health records system, a health informa-
tion exchange, or an e-prescribing system.’’; 
(B) in paragraph (7), by striking ‘‘phar-
macy’’ and inserting ‘‘pharmacist’’; and 
(C) in paragraph (8), by striking ‘‘and the 
District of Columbia’’ and inserting ‘‘, the Dis-
trict of Columbia, and any commonwealth or 
territory of the United States’’; and 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(15) by amending subsection (o), as redesig-
nated by paragraph (12), to read as follows: 
‘‘(o) AUTHORIZATION
OF
APPROPRIATIONS.—To 
carry out this section, there is authorized to be appro-
priated $10,000,000 for each of fiscal years from 2016 
through 2020.’’. 
SEC. 5. REAUTHORIZATION OF BYRNE JUSTICE ASSIST-
ANCE GRANT PROGRAM. 
Section 508 of title I of the Omnibus Crime Control 
and Safe Streets Act of 1968 (42 U.S.C. 3758) is amend-
ed by striking ‘‘2006 through 2012’’ and inserting ‘‘2016 
through 2020’’. 
SEC. 6. AWARENESS CAMPAIGNS. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services shall advance the education and aware-
ness of the public, providers, patients, and other appro-
priate stakeholders regarding the risk of abuse of prescrip-
tion opioid drugs if such products are not taken as pre-
scribed. 
(b) DRUG-FREE MEDIA CAMPAIGN.— 
(1) IN GENERAL.—The Office of National Drug 
Control Policy, in coordination with the Secretary of 
Health and Human Services and the Attorney Gen-
eral, shall establish a national drug awareness cam-
paign. 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(2) REQUIREMENTS.—The national drug aware-
ness campaign under paragraph (1) shall— 
(A) take into account the association be-
tween prescription opioid abuse and heroin use; 
(B) emphasize the similarities between her-
oin and prescription opioids and the effects of 
heroin and prescription opioids on the human 
body; and 
(C) bring greater public awareness to the 
dangerous effects of fentanyl when mixed with 
heroin or abused in a similar manner. 
(3) AVAILABLE
FUNDS.—Funds for the na-
tional drug awareness campaign may be derived 
from amounts appropriated to the Office of National 
Drug Control Policy and otherwise available for obli-
gation and expenditure. 
SEC. 7. NALOXONE DEMONSTRATION GRANTS. 
(a) DEFINITIONS.—In this section— 
(1) the term ‘‘eligible entity’’ means a State, a 
unit of local government, or a tribal government; 
(2) the term ‘‘first responder’’ includes fire-
fighters, law enforcement officers, paramedics, emer-
gency medical technicians, and other individuals (in-
cluding employees of legally organized and recog-
nized volunteer organizations, whether compensated 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
or not), who, in the course of professional duties, re-
spond to fire, medical, hazardous material, or other 
similar emergencies; and 
(3) the term ‘‘opioid overdose reversal drug’’ 
means a drug that, when administered, reverses in 
whole or part the pharmacological effects of an 
opioid overdose in the human body. 
(b) PROGRAM AUTHORIZED.—The Attorney General, 
in coordination with the Secretary of Health and Human 
Services and the Director of the Office of National Drug 
Control Policy, may make grants to eligible entities to cre-
ate not more than 8 demonstration programs to allow 
properly trained first responders to prevent prescription 
opioid and heroin overdose death by administering an 
opioid overdose reversal drug to an individual who has ex-
perienced overdose or who has been determined to have 
likely experienced overdose. 
(c) APPLICATION.— 
(1) IN GENERAL.—To be eligible to receive a 
grant under this section, an entity shall submit an 
application to the Attorney General, at such time, in 
such manner, and accompanied by such information 
as the Attorney General shall require, and— 
(A) that meets the criteria for selection 
under paragraph (2); and 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(B) that describes— 
(i) the evidence-based methodology 
and outcome measures that will be used to 
evaluate the program funded with a grant 
under this section, and specifically explain 
how such measurements will provide valid 
measures of the impact of the program; 
(ii) how the program could be broadly 
replicated if demonstrated to be effective; 
(iii) how the eligible entity will coordi-
nate with their corresponding State sub-
stance abuse agency to identify protocols 
and resources that are available to victims 
and families, including information on 
treatment and recovery resources; and 
(iv) how the demonstration program 
will continue with State, local, or private 
funding after the expiration of the grant. 
(2) CRITERIA FOR SELECTION.—The Attorney 
General may award grants to eligible entities that 
demonstrate an institutional need for technical sup-
port and lack existing infrastructure in order to im-
plement and train first responders to carry out a 
demonstration program under paragraph (b). 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(3) PRIORITY
CONSIDERATION.—In awarding 
grants under this section, the Attorney General shall 
give priority to an eligible entity located in a State 
that provides civil liability protection for first re-
sponders administering an opioid overdose reversal 
drug to counteract opioid overdoses by— 
(A) enacting legislation that provides such 
civil liability protection; and 
(B) providing a certification by the attor-
ney general of the State that the attorney gen-
eral has— 
(i) reviewed any applicable civil liabil-
ity protection law to determine the applica-
bility of the law with respect to first re-
sponders who may administer an opioid 
overdose reversal drug to individuals rea-
sonably believed to be suffering from 
opioid overdose; and 
(ii) concluded that the law described 
in subparagraph (A) provides adequate 
civil liability protection applicable to such 
persons. 
(d) USE OF FUNDS.—An eligible entity shall use a 
grant received under this section to— 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(1) make an opioid overdose reversal drug, 
which may include naloxone, available to be carried 
and administered by first responders; 
(2) train and provide resources for first re-
sponders, on carrying and administrating such 
opioid overdose reversal drug for the prevention of 
prescription opioid and heroin overdose deaths; and 
(3) establish processes, protocols, and mecha-
nisms for referral to treatment. 
(e) TECHNICAL SUPPORT.—The Attorney General 
shall provide individualized technical support, as re-
quested, to grant recipients under this section to assist 
with implementation of the demonstration program. 
(f) GRANT DURATION.—A demonstration project 
grant shall be for a period of 3 years. 
(g) EVALUATION.—Following the first grant year, a 
recipient of a grant awarded under this section shall re-
port to the Attorney General on an annual basis — 
(1) the number of first responders equipped 
with an opioid overdose reversal drug for the preven-
tion of fatal prescription opioid and heroin overdose; 
(2) the number of prescription opioid and her-
oin overdoses reversed by first responders; 
(3) the number of calls for service related to 
prescription opioid and heroin overdose; and 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS
(4) the extent to which overdose victims and 
families receive information about treatment services 
and available data describing treatment admissions. 
(h) REPORT TO CONGRESS.—The Attorney General 
shall submit an annual report to the appropriate commit-
tees of Congress aggregating the data received from the 
grant recipients and evaluating the outcomes achieved by 
the demonstration projects funded under this section. 
SEC. 8. OFFSET. 
It is the sense of Congress that the amounts ex-
pended to carry out this Act and the amendments made 
by this Act should be offset by a corresponding reduction 
in Federal non-defense discretionary spending. 
Æ 
VerDate Sep 11 2014 
21:18 Jun 19, 2015
Jkt 049200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6301
E:\BILLS\H2805.IH
H2805
srobinson on DSK5SPTVN1PROD with BILLS